|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023688,
umls-concept:C0205460,
umls-concept:C0205531,
umls-concept:C0220781,
umls-concept:C0226896,
umls-concept:C0243077,
umls-concept:C0332256,
umls-concept:C0439855,
umls-concept:C0441655,
umls-concept:C0442027,
umls-concept:C0470187,
umls-concept:C1527415,
umls-concept:C1707689,
umls-concept:C1883254
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-11-20
|
|
pubmed:abstractText |
We found the novel selective and orally available non-amidine TF/FVIIa complex inhibitor 21e, 4-({[(1S)-(aminocarbonyl)-3-methylbutyl]amino}carbonyl)-2'-({[4- (aminomethyl)phenyl]amino}carbonyl)-4'-(methylamino)biphenyl-2- carboxylic acid. The derivatives were synthesized by conversions of the isobutyl moiety and the introduction of alkylamino groups to 4'-position of the central phenyl ring of compounds 2a and 2b reported previously. Some compounds show increased in vitro anti-TF/FVIIa and PT prolongation activities. Among them, compound 21e reached and sustained micromolar plasma concentration levels of up to 2h after oral administration in mice. Moreover, compound 21e did not prolong the bleeding time even at the highest dose level in cynomolgus monkeys, while PT was prolonged 3.7-fold increases at this dose.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0968-0896
|
|
pubmed:author |
pubmed-author:HirayamaFukushiF,
pubmed-author:IshiharaTsukasaT,
pubmed-author:KawasakiTomihisaT,
pubmed-author:KoikeTakanoriT,
pubmed-author:MiuraMasanoriM,
pubmed-author:NiimiTatsuyaT,
pubmed-author:OhtaMitsuakiM,
pubmed-author:OkadaMinoruM,
pubmed-author:Sakai-MoritaniYumikoY,
pubmed-author:SakamotoShuichiS,
pubmed-author:SekiNorioN,
pubmed-author:ShigenagaTakeshiT,
pubmed-author:TagawaAyakoA,
pubmed-author:TsukamotoShin-IchiS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
160-73
|
|
pubmed:meshHeading |
pubmed-meshheading:17064913-Administration, Oral,
pubmed-meshheading:17064913-Animals,
pubmed-meshheading:17064913-Binding Sites,
pubmed-meshheading:17064913-Biphenyl Compounds,
pubmed-meshheading:17064913-Blood Coagulation Factor Inhibitors,
pubmed-meshheading:17064913-Drug Design,
pubmed-meshheading:17064913-Drug Evaluation, Preclinical,
pubmed-meshheading:17064913-Factor VIIa,
pubmed-meshheading:17064913-Humans,
pubmed-meshheading:17064913-Hydrogen Bonding,
pubmed-meshheading:17064913-Ligands,
pubmed-meshheading:17064913-Lipoproteins,
pubmed-meshheading:17064913-Macaca fascicularis,
pubmed-meshheading:17064913-Male,
pubmed-meshheading:17064913-Methylamines,
pubmed-meshheading:17064913-Mice,
pubmed-meshheading:17064913-Mice, Inbred ICR,
pubmed-meshheading:17064913-Models, Molecular,
pubmed-meshheading:17064913-Molecular Structure,
pubmed-meshheading:17064913-Protein Structure, Secondary,
pubmed-meshheading:17064913-Sensitivity and Specificity,
pubmed-meshheading:17064913-Stereoisomerism,
pubmed-meshheading:17064913-Structure-Activity Relationship,
pubmed-meshheading:17064913-Thromboplastin
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands.
|
|
pubmed:affiliation |
Institute for Drug Discovery Research, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. masanori-miura@jp.astellas.com
|
|
pubmed:publicationType |
Journal Article
|
